AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28626589 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (Ex) and lunch labelled as high in fat (HF)
Number of subjects: 14
Study 28626589 — intervention group
Group type: COMPARATOR
Intervention: Rest and lunch labelled as low in fat (LF)
Number of subjects: 14
Study 28626589 — intervention group
Group type: COMPARATOR
Intervention: Rest and lunch labelled as high in fat (HF)
Number of subjects: 14
Study 26190132 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication review by an experienced hospital pharmacist within the ED
Number of subjects: 0
Study 23827009 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Cat (experimental group)
Number of subjects: 130
Study 23827009 — intervention group
Group type: COMPARATOR
Intervention: No program (control group)
Number of subjects: 130
Study 22573261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight (LW) mesh
Number of subjects: 392
Study 22573261 — intervention group
Group type: COMPARATOR
Intervention: Heavyweight (HW) mesh
Number of subjects: 392
Study 20003464 — intervention group
Group type: EXPERIMENTAL
Intervention: S. sonnei
Number of subjects: 0
Study 20003464 — intervention group
Group type: EXPERIMENTAL
Intervention: S. flexneri
Number of subjects: 0
Study 17395895 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (DRO), 7.5 mg, single dose
Number of subjects: 52
Study 17395895 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 52
Study 15310354 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position (LL)
Number of subjects: 100
Study 15310354 — intervention group
Group type: COMPARATOR
Intervention: Supine, wedged position (SW)
Number of subjects: 100
Study 11730399 — intervention group
Group type: EXPERIMENTAL
Intervention: Small trials with inadequate allocation sequence generation
Number of subjects: 190
Study 11730399 — intervention group
Group type: EXPERIMENTAL
Intervention: Small trials with inadequate allocation concealment
Number of subjects: 190
Study 11730399 — intervention group
Group type: EXPERIMENTAL
Intervention: Small trials with no double blinding
Number of subjects: 190
Study 11730399 — intervention group
Group type: COMPARATOR
Intervention: Large trials with adequate generation of the allocation sequence
Number of subjects: 190
Study 11730399 — intervention group
Group type: COMPARATOR
Intervention: Large trials with adequate allocation concealment
Number of subjects: 190
Study 11730399 — intervention group
Group type: COMPARATOR
Intervention: Large trials with adequate double blinding
Number of subjects: 190
Study 11730399 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported follow-up
Number of subjects: 190
Study 9743306 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (500 mg m(‐2)), epirubicin (60 mg m(‐2)), cyclophosphamide (500 mg m(‐2)) administered in four weekly doses
Number of subjects: 173
Study 9743306 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (500 mg m(‐2)), epirubicin (60 mg m(‐2)), cyclophosphamide (500 mg m(‐2)) administered in every‐4‐week dose
Number of subjects: 173
Study 9743306 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (500 mg m(‐2)), epirubicin (60 mg m(‐2)), cyclophosphamide (500 mg m(‐2))
Number of subjects: 173
Study 9815951 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 0.5 mg/day
Number of subjects: 13
Study 9815951 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg/day
Number of subjects: 13
Study 2299605 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intravesical injections of 250 mg of prostaglandin F2 alpha (PGF2 alpha) (n = 23)
Number of subjects: 69
Study 2299605 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 10‐mg PGE2 vaginal suppository (n = 22)
Number of subjects: 69
Study 2299605 — intervention group
Group type: COMPARATOR
Intervention: Daily saline injection to the bladder (control group, n = 24)
Number of subjects: 69
Study 7441695 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction from professional patients
Number of subjects: 40
Study 7441695 — intervention group
Group type: COMPARATOR
Intervention: Instruction from gynecologist with a clinic patient (Control)
Number of subjects: 40
Study 29388856 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (Group A)
Number of subjects: 120
Study 29388856 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (Group L)
Number of subjects: 120
Study 29388856 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 120
Study 26714731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 220
Study 26714731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 25649801 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose B vitamin therapy
Number of subjects: 3680
Study 25649801 — intervention group
Group type: COMPARATOR
Intervention: Low-dose B vitamin therapy
Number of subjects: 3680
Study 24199747 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prescription and devices for monitoring of risk factors with a smartphone data portal equipped with a mobile health application
Number of subjects: 149
Study 24199747 — intervention group
Group type: COMPARATOR
Intervention: Exercise prescription
Number of subjects: 149
Study 21393611 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sirolimus plus enalapril and atorvastatin (SRL group, n = 14)
Number of subjects: 23
Study 21393611 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sirolimus plus enalapril and atorvastatin (SRL group)
Number of subjects: 23
Study 21393611 — intervention group
Group type: COMPARATOR
Intervention: Enalapril plus atorvastatin (CONTROL group, n = 9)
Number of subjects: 23
Study 21393611 — intervention group
Group type: COMPARATOR
Intervention: Enalapril plus atorvastatin (CONTROL group)
Number of subjects: 23
Study 19590473 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine injections
Number of subjects: 34
Study 19590473 — intervention group
Group type: COMPARATOR
Intervention: N-saline injections
Number of subjects: 34
Study 16836814 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (Etch and Prime 3.0) with Degufill Mineral RBC
Number of subjects: 15
Study 16836814 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-bottle adhesive system (Gluma Solid Bond) with Wet Bond technique
Number of subjects: 15
Study 16836814 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-bottle adhesive system (Gluma Solid Bond) with Dry Bond technique
Number of subjects: 15
Study 16836814 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-bottle adhesive system (Gluma Solid Bond) with Wet Bond vs Dry Bond
Number of subjects: 15
Study 14689341 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 686
Study 14689341 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 686
Study 10868865 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone monotherapy (600 mg daily)
Number of subjects: 758
Study 10868865 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone with sulfonylurea (600 mg daily)
Number of subjects: 758
Study 10868865 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone with insulin (600 mg daily)
Number of subjects: 758
Study 10868865 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (all combinations, 600 mg daily)
Number of subjects: 758
Study 1839798 — intervention group
Group type: EXPERIMENTAL
Intervention: 17‐beta estradiol valerianate (E2) (2 mg)
Number of subjects: 44
Study 1839798 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized E2 (2 mg) plus estriol (E3) (1 mg)
Number of subjects: 44
Study 1839798 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + E3
Number of subjects: 44
Study 1839798 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA
Number of subjects: 44
Study 1839798 — intervention group
Group type: COMPARATOR
Intervention: Low calorie diet
Number of subjects: 44
Study 6222901 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) 250 mg twice a day
Number of subjects: 36
Study 6222901 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) 250 mg
Number of subjects: 36
Study 6222901 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG)
Number of subjects: 36
Study 30314739 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention program
Number of subjects: 127
Study 30314739 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 127
Study 29138224 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Metformin (E + M)
Number of subjects: 0
Study 29138224 — intervention group
Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 0
Study 26325273 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-sapphire laser trabeculoplasty (TLT)
Number of subjects: 37
Study 26325273 — intervention group
Group type: COMPARATOR
Intervention: Standard Q-Switched Nd:YAG laser trabeculoplasty (SLT)
Number of subjects: 37
Study 25304007 — intervention group
Group type: EXPERIMENTAL
Intervention: CT/TT genotypes of XRCC2 C41657T
Number of subjects: 508
Study 25304007 — intervention group
Group type: EXPERIMENTAL
Intervention: XRCC2 protein expression in CRC patients with CT/TT genotypes
Number of subjects: 508
Study 25304007 — intervention group
Group type: COMPARATOR
Intervention: G4234C polymorphisms of XRCC2
Number of subjects: 508
Study 22067089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified Medical therapy
Number of subjects: 622
Study 22067089 — intervention group
Group type: COMPARATOR
Intervention: Standard Medical therapy
Number of subjects: 622
Study 22067089 — intervention group
Group type: COMPARATOR
Intervention: Resuscitation orders
Number of subjects: 622
Study 20861211 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee mannooligosaccharides (MOS) beverage (4 g/d)
Number of subjects: 54
Study 20861211 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 54
Study 18227044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of alanyl-glutamine (Gln) with standard total parenteral nutrition (TPN) for 1 week
Number of subjects: 50
Study 18227044 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control) with standard total parenteral nutrition (TPN) for 1 week
Number of subjects: 50
Study 15943942 — intervention group
Group type: EXPERIMENTAL
Intervention: Timeline Follow-Back Instrument (TLFB)
Number of subjects: 0
Study 12297407 — intervention group
Group type: EXPERIMENTAL
Intervention: therapeutic vaccination with pre‐S1, pre‐S2 and S antigenic components of HBV
Number of subjects: 22
Study 10626187 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein (AFP) levels in anti-HCV positive patients with HCC
Number of subjects: 336
Study 10626187 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-HCV positive patients without HCC)
Number of subjects: 336
Study 8560112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Diltiazem (DTZ)
Number of subjects: 43
Study 8560112 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Nitroglycerin (NTG)
Number of subjects: 43
Study 2075139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine plus pirenzepine (50 mg before bedtime)
Number of subjects: 70
Study 2075139 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate (4.0 g daily)
Number of subjects: 70
Study 6828827 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation programme including physical exercise, counselling of patients and relatives, and social measures over a 3-month period
Number of subjects: 171
Study 6828827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rehabilitation programme)
Number of subjects: 171
Study 31748259 — intervention group
Group type: EXPERIMENTAL
Intervention: High genetically predicted plasma homocysteine levels (PHL)
Number of subjects: 7004
Study 31748259 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for women
Number of subjects: 7004
Study 31748259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analyses
Number of subjects: 7004
Study 31748259 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-Egger and weighted median regression
Number of subjects: 7004
Study 29395715 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-length clear corneal incisions (≥1.75 mm)
Number of subjects: 120
Study 29395715 — intervention group
Group type: COMPARATOR
Intervention: Short-length clear corneal incisions (<1.75 mm)
Number of subjects: 120
Study 26371143 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 518
Study 26371143 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 518
Study 25344019 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 821
Study 25344019 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP risk factors
Number of subjects: 821
Study 25344019 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematoma risk factors
Number of subjects: 821
Study 24132044 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based physical activity intervention
Number of subjects: 199
Study 20571386 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine/6-mercaptopurine
Number of subjects: 0
Study 20571386 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroimidazole antibiotics
Number of subjects: 0
Study 20571386 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study 20571386 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation and ileocolonoscopy
Number of subjects: 0
Study 20571386 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative immunomodulators and antitumor necrosis factor agents
Number of subjects: 0
Study 18615321 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach Treatment Program (OTP)
Number of subjects: 124
Study 18615321 — intervention group
Group type: COMPARATOR
Intervention: Standard Addiction Care Services (Control)
Number of subjects: 124
Study 16041475 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOFlipid 20%
Number of subjects: 33
Study 12825037 — intervention group
Group type: EXPERIMENTAL
Intervention: TCRFTA
Number of subjects: 90
Study 12825037 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 90
Study 12825037 — intervention group
Group type: COMPARATOR
Intervention: Sham-placebo
Number of subjects: 90
Study 10491351 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine test
Number of subjects: 49
Study 10491351 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral analysis (alpha(c) index)
Number of subjects: 49
Study 10491351 — intervention group
Group type: COMPARATOR
Intervention: Controlled breathing
Number of subjects: 49
Study 8677455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose level 1 (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Number of subjects: 12
Study 8677455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose level 2 (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Number of subjects: 12
Study 8677455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose level 3 (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Number of subjects: 12
Study 8677455 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment regimen (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Number of subjects: 12
Study 1990895 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1-3 mg.kg-1 injected over 10-30 s)
Number of subjects: 90
Study 1990895 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1-3 mg.kg-1 injected over 10-30 s) with halothane (1-3%)
Number of subjects: 90
Study 6760217 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofensine (mean daily dose of 57.5 mg for 3 weeks)
Number of subjects: 40
Study 6760217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6760217 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofensine
Number of subjects: 40
Study 30991863 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate combined with chemotherapy (taxane, irinotecan, and fluorouracil)
Number of subjects: 119
Study 30991863 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotherapy only: taxane, irinotecan, and fluorouracil)
Number of subjects: 119
Study 29705555 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-9701
Number of subjects: 40
Study 29705555 — intervention group
Group type: COMPARATOR
Intervention: Domperidone
Number of subjects: 40
Study 26375357 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-chocolate condition
Number of subjects: 120
Study 26375357 — intervention group
Group type: COMPARATOR
Intervention: Avoid-chocolate condition
Number of subjects: 120
Study 24458212 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein supplementation (HP)
Number of subjects: 18
Study 24458212 — intervention group
Group type: COMPARATOR
Intervention: Standard meal supplementation (SM)
Number of subjects: 18
Study 23019834 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (10 mg/5 mL concentration)
Number of subjects: 16
Study 23019834 — intervention group
Group type: COMPARATOR
Intervention: Artificial saliva (control)
Number of subjects: 16
Study 20937118 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX and Bevacizumab
Number of subjects: 0
Study 20937118 — intervention group
Group type: COMPARATOR
Intervention: CAPOX alone
Number of subjects: 0
Study 17215176 — intervention group
Group type: EXPERIMENTAL
Intervention: high-CHO(food+fibre)
Number of subjects: 18
Study 17215176 — intervention group
Group type: EXPERIMENTAL
Intervention: high-CHO(drink+fibre)
Number of subjects: 18
Study 17215176 — intervention group
Group type: COMPARATOR
Intervention: high-CHO(food control)
Number of subjects: 18
Study 17215176 — intervention group
Group type: COMPARATOR
Intervention: high-CHO(drink control)
Number of subjects: 18
Study 17215176 — intervention group
Group type: EXPERIMENTAL
Intervention: high-CHO breakfasts
Number of subjects: 18
Study 15266731 — intervention group
Group type: EXPERIMENTAL
Intervention: 30,000 rpm electric rotary drill with irrigation
Number of subjects: 100
Study 15266731 — intervention group
Group type: COMPARATOR
Intervention: 90,000 rpm handpiece
Number of subjects: 100
Study 12578245 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Effort Rating Table (CERT)
Number of subjects: 69
Study 12578245 — intervention group
Group type: COMPARATOR
Intervention: Borg 6-20 Rating of Perceived Exertion (RPE) scale
Number of subjects: 69
Study 9439022 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 32
Study 9439022 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 32
Study 9439022 — intervention group
Group type: COMPARATOR
Intervention: Mock transcutaneous electrical nerve stimulation
Number of subjects: 32
Study 8586837 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infected patients with oral hairy leukoplakia
Number of subjects: 91
Study 8586837 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic HIV-1 infected persons
Number of subjects: 91
Study 8586837 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 91
Study 8586837 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infected patients
Number of subjects: 91
Study 8586837 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic HIV-1 infected persons
Number of subjects: 91
Study 8586837 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infected patients with and without hairy leukoplakia
Number of subjects: 91
Study 2670657 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg o.d.)
Number of subjects: 13
Study 2670657 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg b.i.d.)
Number of subjects: 13
Study 68225 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular polyglycolic acid (P.G.A.) sutures
Number of subjects: 127
Study 68225 — intervention group
Group type: COMPARATOR
Intervention: Interrupted nylon skin sutures
Number of subjects: 127
Study 31264313 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g hesperidin capsule
Number of subjects: 50
Study 31264313 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 50
Study 27864156 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 122
Study 27864156 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 122
Study 26614145 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 120
Study 26614145 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone
Number of subjects: 120
Study 26614145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23728544 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy Bond (3M ESPE) with three adhesive layers
Number of subjects: 90
Study 23728544 — intervention group
Group type: COMPARATOR
Intervention: Scotchbond 1XT (3M ESPE) per manufacturer's instructions
Number of subjects: 90
Study 23728544 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy Bond (3M ESPE) with one to four additional adhesive layers
Number of subjects: 90
Study 23728544 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 1XT (3M ESPE) with three and four layers
Number of subjects: 90
Study 21609298 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-support information combined with personal decision-making support (counselling/peer meetings)
Number of subjects: 0
Study 21609298 — intervention group
Group type: COMPARATOR
Intervention: Decision-support information only (services/quality indicators)
Number of subjects: 0
Study 19924244 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diabetic individuals carrying the T allele of TCF7L2 polymorphism rs7903146
Number of subjects: 889
Study 19924244 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diabetic individuals carrying the CT/TT genotypes
Number of subjects: 889
Study 16828804 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg
Number of subjects: 876
Study 16828804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 876
Study 12849664 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 643
Study 12849664 — intervention group
Group type: COMPARATOR
Intervention: No lipid-lowering therapy
Number of subjects: 643